Document is current
Any future updates will be listed below
-
Authors
Charles Cano, Fiorella https://orcid.org/0009-0006-3941-7497
Kloos, Arnold
Hebalkar, Rucha Y.
Plenge, Thomas
Geffers, Robert https://orcid.org/0000-0003-4409-016X
Kirchhoff, Hanna
Kattre, Nadine
Görlich, Kerstin
Büsche, Guntram
Shcherbata, Halyna R. https://orcid.org/0000-0002-3855-0345
Scherr, Michaela
Döhner, Konstanze
Gabdoulline, Razif
Heuser, Michael https://orcid.org/0000-0001-5318-9044
- License Information
-
More Information
Article History
Received: 12 July 2024
Revised: 1 February 2025
Accepted: 13 March 2025
First Online: 27 March 2025
Competing interests
: MH declares honoraria from Abbvie, Eurocept, Jazz Pharmaceuticals, Janssen, Novartis, Takeda, paid consultancy for Abbvie, Agios, BMS, Daiichi Sankyo, Glycostem, Jazz Pharmaceuticals, Kura Oncology, Novartis, Pfizer, PinotBio, Roche, Tolremo, and research funding to his institution from Abbvie, Agios, Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Glycostem, Jazz Pharmaceuticals, Loxo Oncology, Novartis, Pfizer, PinotBio, Roche. KD declares research funding from Novartis, Astellas, Agios, BMS/Celgene, honoraria from Novartis, BMS/Celgene, Daiichi Sankyo, Jazz, Roche, AOP, Abbvie and membership advisory committee: Abbvie. The other authors declare no competing financial interests.
